Randomized Pilot Study of Ustekinumab for Subjects with Chronic Atopic Dermatitis Who Have Sub-optimal Response to Prior Therapy

July 28, 2013

This study is currently recruiting participants. Verified March 2013 by Rockefeller University

Sponsor:

Rockefeller University

Information provided by:

Rockefeller University

ClinicalTrials.gov Identifier:

NCT01806662

Purpose:

We are carrying out a clinical trial with the drug Stelara (ustekinumab), which is already FDA approved for Psoriasis, in patients with moderate to severe eczema, ages 18 years – 75 years.  In order to be eligible, a patient must have failed at least topical steroids and either light therapy or oral steroids. Patients will have 15 visits over the course of a year at Rockefeller University, which is located on the Upper East Side of New York City. Patients are guaranteed to receive 3 doses of Stelara throughout the study. Patients will also be allowed to use Triamcinolone 0.025% during the course of the study.  If the medication is effective at clearing a patients eczema, they will be eligible to receive an extra dose at the completion of the study.  For full participation, patients are compensated $600.

Name/Title of the Principal Investigator:

Dr. Emma Guttman, MD/PhD

Contact Information:

Saakshi Khattri, MD – Clinical Reserch Fellow
1230 York Avenue
New York, NY  10065
Business number: 212-327-8354/8333
Fax number: 212-327-8232
Recruitment Office 1-800-782-2737
email: skhattri@rockefeller.edu

For more information, please visit:

www.clinicaltrials.gov

Please click here to return to the Clinical Trials main page